Adherex Technologies Inc.

Adherex Technologies Inc.

September 08, 2009 17:39 ET

Adherex Names Robert Andrade Chief Financial Officer

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - Sept. 8, 2009) - Adherex Technologies Inc. (TSX:AHX), announced today that the Company has appointed Robert Andrade as its new Chief Financial Officer. "I have known Robert professionally for more than 12 years. He has a solid financial background required for the new corporate direction of the Company," said Rosty Raykov, CEO of Adherex.

Mr. Andrade, an existing Vice President and Board member of Adherex, is an accomplished executive with over 12 years of relevant financial experience that includes numerous financings and merger and acquisitions transactions. Currently, Mr. Andrade is also a General Partner at DCML, a private investment partnership. Mr. Andrade's financial experience includes senior investment positions at Millennium Partners L.P., and Caxton Associates, as well as advisory positions at Trimaran Capital Partners and Bear Stearns.

Jim Klein, the Company's previous Chief Financial Officer is no longer with the Company.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company focused on the development of eniluracil and 5-fluorouaricil.

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding our development plans and the expected funding, timing and results of our development as well as our efforts to pursue strategic alternatives. We can provide no assurance that development will proceed as currently anticipated, that previous results will be predictive of future outcomes, that the expected funding, timing or results of our development will be realized, or that we will be able to form strategic collaborations or partnerships with other companies. We are subject to various risks, including our near term need for additional capital to fund our operations, current and anticipated conditions in the economy and financial markets, our history of losses, our ability to continue to meet the listing requirements of the TSX, the uncertainties of clinical trials, drug development and regulatory review, the early stage of our product candidates, our reliance on collaborative partners, and other risks inherent to the biopharmaceutical industry. For a more detailed discussion of related risk factors, please refer to our public filings available at

Contact Information

  • Adherex Technologies Inc.
    Rosty Raykov
    Chief Executive Officer